1. Home
  2. ELME vs PLX Comparison

ELME vs PLX Comparison

Compare ELME & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elme Communities

ELME

Elme Communities

HOLD

Current Price

$2.17

Market Cap

198.2M

Sector

Real Estate

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.97

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELME
PLX
Founded
1960
1993
Country
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
230.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ELME
PLX
Price
$2.17
$2.97
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$14.25
$12.00
AVG Volume (30 Days)
5.6M
1.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
33.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$14.29
Revenue Next Year
N/A
$16.65
P/E Ratio
N/A
$43.14
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$1.32
52 Week High
$17.68
$3.10

Technical Indicators

Market Signals
Indicator
ELME
PLX
Relative Strength Index (RSI) 8.35 72.63
Support Level $2.15 $2.81
Resistance Level $2.26 $3.03
Average True Range (ATR) 0.07 0.17
MACD 0.51 0.03
Stochastic Oscillator 46.88 93.00

Price Performance

Historical Comparison
ELME
PLX

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: